Royal Bank of Canada Analysts Give Medidata Solutions (MDSO) a $82.00 Price Target

Medidata Solutions (NASDAQ:MDSO) has been given a $82.00 price objective by analysts at Royal Bank of Canada in a research report issued to clients and investors on Thursday. The brokerage currently has a “hold” rating on the stock. Royal Bank of Canada’s target price suggests a potential upside of 26.21% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the company. TheStreet cut Medidata Solutions from a “b” rating to a “c+” rating in a research note on Thursday, December 14th. Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Wells Fargo & Co decreased their target price on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a report on Friday, October 27th. SunTrust Banks reiterated a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a report on Friday, October 27th. Finally, Deutsche Bank assumed coverage on Medidata Solutions in a report on Friday, December 8th. They issued a “buy” rating and a $78.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $83.00.

Shares of Medidata Solutions (MDSO) traded up $2.36 during midday trading on Thursday, hitting $64.97. The stock had a trading volume of 1,590,768 shares, compared to its average volume of 643,297. Medidata Solutions has a twelve month low of $54.36 and a twelve month high of $85.92. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.50 and a quick ratio of 3.37. The firm has a market capitalization of $3,660.24, a PE ratio of 87.80, a PEG ratio of 3.24 and a beta of 1.58.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.10. Medidata Solutions had a return on equity of 11.59% and a net margin of 8.14%. The business had revenue of $141.20 million during the quarter, compared to analysts’ expectations of $140.65 million. During the same period in the previous year, the firm posted $0.33 earnings per share. The company’s revenue was up 13.4% on a year-over-year basis. analysts expect that Medidata Solutions will post 0.93 EPS for the current year.

In other Medidata Solutions news, CFO Rouven Bergmann sold 3,000 shares of Medidata Solutions stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $70.00, for a total transaction of $210,000.00. Following the completion of the sale, the chief financial officer now directly owns 84,775 shares of the company’s stock, valued at approximately $5,934,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Pray sold 5,944 shares of Medidata Solutions stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $70.47, for a total value of $418,873.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,010 shares of company stock valued at $1,962,206. 5.80% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp lifted its holdings in Medidata Solutions by 27.7% during the 2nd quarter. State Street Corp now owns 1,828,913 shares of the company’s stock worth $143,022,000 after buying an additional 396,793 shares during the last quarter. American Century Companies Inc. lifted its holdings in Medidata Solutions by 21.3% during the 4th quarter. American Century Companies Inc. now owns 1,439,710 shares of the company’s stock worth $91,234,000 after buying an additional 252,867 shares during the last quarter. Global Thematic Partners LLC lifted its holdings in Medidata Solutions by 37.3% during the 4th quarter. Global Thematic Partners LLC now owns 1,429,138 shares of the company’s stock worth $90,564,000 after buying an additional 388,608 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in Medidata Solutions by 2,994.6% during the 3rd quarter. Canada Pension Plan Investment Board now owns 1,151,200 shares of the company’s stock worth $89,863,000 after buying an additional 1,114,000 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Medidata Solutions by 10.5% during the 2nd quarter. Janus Henderson Group PLC now owns 882,164 shares of the company’s stock worth $68,985,000 after buying an additional 84,161 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/10/royal-bank-of-canada-analysts-give-medidata-solutions-mdso-a-82-00-price-target.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply